Rockefeller Capital Management
ALXN

Rockefeller Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Rockefeller Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-13,253
Closed -$2.43M – 3962
2021
Q2 		$2.43M Buy
13,253
+3,503
+36% +$601K 0.01% 668
2021
Q1 		$1.49M Sell
9,750
-218
-2% -$33.7K 0.01% 665
2020
Q4 		$1.56M Buy
9,968
+1,771
+22% +$228K 0.01% 582
2020
Q3 		$937K Buy
8,197
+554
+7% +$59.8K 0.01% 612
2020
Q2 		$858K Sell
7,643
-2,191
-22% -$233K 0.01% 576
2020
Q1 		$883K Sell
9,834
-1,831
-16% -$180K 0.01% 500
2019
Q4 		$1.26M Buy
11,665
+1,021
+10% +$109K 0.02% 412
2019
Q3 		$1.04M Sell
10,644
-310
-3% -$34.9K 0.01% 383
2019
Q2 		$1.43M Sell
10,954
-2,818
-20% -$363K 0.02% 297
2019
Q1 		$1.86M Buy
13,772
+2,785
+25% +$346K 0.03% 275
2018
Q4 		$1.07M Buy
10,987
+425
+4% +$50.2K 0.02% 239
2018
Q3 		$1.47M Buy
10,562
+1,986
+23% +$249K 0.02% 187
2018
Q2 		$1.06M Buy
8,576
+26
+0.3% +$3.04K 0.02% 206
2018
Q1 		$953K Buy
+8,550
New +$1.02M 0.02% 219

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Rockefeller Capital Management's ALXN Position: Q3 2021 in Review

Rockefeller Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 13,253 shares — an estimated $2.43M sold.

Rockefeller Capital Management first reported a position in ALXN in Q1 2018 and held it in 14 quarters. The position peaked at $2.43M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Rockefeller Capital Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Rockefeller Capital Management sold 13,253 Alexion Pharmaceuticals shares in Q3 2021, an estimated $2.43M.
  • Rockefeller Capital Management first reported a position in Alexion Pharmaceuticals in Q1 2018 and held it in 14 quarters.
  • Rockefeller Capital Management's Alexion Pharmaceuticals position peaked at $2.43M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Rockefeller Capital Management's 13F filing for Q3 2021, filed 12 Nov 2021.